Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa (Q38358517)

2 September 2017

title

Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa (English)

1 reference

2 September 2017

0 references

1 reference

J M van Kampen

1 reference

2 September 2017

A Jon Stoessl

series ordinal

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

2 September 2017

1 reference

2 September 2017

volume

116

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

307-314

1 reference

Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Striatal D1 dopamine receptor morphochemistry following continuous or intermittent l-DOPA replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Levodopa therapy: consequences of the nonphysiologic replacement of dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Postnatal ontogeny of dopamine D3 receptors in the mouse brain: autoradiographic evidence for a transient cortical expression

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Neuronal circuitry and synaptic connectivity of the basal ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Dopamine D3 receptor antisense reduces neuropeptide mRNA levels in rat nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

The antisense strategy applied to the study of dopamine D3 receptor functions in rat forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Gene inhibition using antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Antisense strategies in neurobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4522%2802%2900548-1

7 January 2021

10.1016/S0306-4522(02)00548-1

Identifiers

DOI

1 reference

2 September 2017

1 reference